In NAFLD patients, the rates of lipogenesis are three-fold higher than healthy individuals, and SREBP1c is chronically activated and increases lipogenic activity, resulting in progression of hepatic steatosis [22,23]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.